News

Catch up on the most impactful trial readouts to come out of ACC 2026.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Catch up on the guideline updates, trial news, and featured content from March 2026.

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

In part 3 of an interview, Michael E. Thase, MD, discusses retreatment timing, safety monitoring, and research priorities following phase 2b GH001 data.

Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.

Data presented at the World Congress of Nephrology highlight faster and higher rates of microscopic hematuria negativity with sibeprenlimab treatment.

Song speaks about JAK inhibitors and their safety in dermatology care settings, contextualizing previous data on adverse events.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia.

Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.

The WHO resolution on kidney health elevates kidney disease as a global health priority, emphasizing early detection, treatment, and system-wide action.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

New OPTN data shows kidney transplant gains from race-free GFR and restored wait times stall, as structural barriers still limit equitable listing access.

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

Indirect data suggest oral semaglutide may reduce weight more than orforglipron, but cross-trial comparisons limit clinical interpretation.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.